Richard Pfenniger, Jr. Biography and Net Worth

Director of Cocrystal Pharma

Mr. Pfenniger is a private investor who served as Interim CEO of Vein Clinics of America, Inc., a privately held company that specializes in the treatment of vein disease, from May 2014 to February 2015, and as Interim CEO of IntegraMed America, Inc., a privately held company that manages outpatient fertility medical centers, from January 2013 to June 2013. He served as CEO and President of Continucare Corporation, a provider of primary care physician and practice management services, from 2003 to 2011, and as Chairman of the Board of Continucare Corporation from 2002 to 2011. Previously, Mr. Pfenniger served as CEO and Vice Chairman of Whitman Education Group, Inc. from 1997 to June 2003. Before that, he served at the IVAX Corporation as COO from 1994 to 1997, and as Senior Vice President-Legal Affairs and General Counsel from 1989 to 1994. He previously was engaged in the private practice of law. Mr. Pfenniger is a director of OPKO Health (Nasdaq: OPK), GP Strategies Corporation (NYSE: GPX) and Asensus Surgical, Inc. (NYSE American: ASXC).

What is Richard C. Pfenniger, Jr.'s net worth?: The estimated net worth of Richard C. Pfenniger, Jr. is at least $477,750.00 as of January 5th, 2024. Pfenniger, Jr. owns 325,000 shares of Cocrystal Pharma stock worth more than $477,750 as of April 18th. This net worth evaluation does not reflect any other investments that Pfenniger, Jr. may own. Learn More about Richard C. Pfenniger, Jr.'s net worth.
How do I contact Richard C. Pfenniger, Jr.?: The corporate mailing address for Pfenniger, Jr. and other Cocrystal Pharma executives is 19805 N. CREEK PARKWAY, BOTHELL WA, 98011. Cocrystal Pharma can also be reached via phone at (305) 425-1780 and via email at [email protected]. Learn More on Richard C. Pfenniger, Jr.'s contact information.
Has Richard C. Pfenniger, Jr. been buying or selling shares of Cocrystal Pharma?: Richard C. Pfenniger, Jr. has not been actively trading shares of Cocrystal Pharma over the course of the past ninety days. Learn More on Richard C. Pfenniger, Jr.'s trading history.
Who are Cocrystal Pharma's active insiders?: Cocrystal Pharma's insider roster includes Richard Pfenniger, Jr. (Director), and Raymond Schinazi (Major Shareholder). Learn More on Cocrystal Pharma's active insiders.

Richard C. Pfenniger, Jr. Insider Trading History at Cocrystal Pharma

Richard C. Pfenniger, Jr. Buying and Selling Activity at Cocrystal Pharma

Cocrystal Pharma Company Overview

Cocrystal Pharma, Inc., a biotechnology company, focuses on the discovery and development of antiviral therapeutic treatments for serious and/or chronic viral diseases. It employs structure-based technologies to create antiviral drugs primarily to treat hepatitis C virus (HCV), influenza virus, coronavirus, and norovirus infections. The company develops CC-31244, a HCV non-nucleoside polymerase inhibitor that has completed Phase II a clinical trial to treat HCV infection; and CC-42344, a PB2 inhibitor that has completed Phase I clinical trial for treating influenza infection. It is also involved in identifying and developing non-nucleoside polymerase inhibitors for norovirus infections. Cocrystal Pharma, Inc. has a license and research collaboration agreement with Merck Sharp & Dohme Corp. to discover and develop proprietary influenza A/B antiviral agents; and a license agreement with Kansas State University Research Foundation to develop antiviral compounds for the treatment of norovirus and coronavirus infections. The company is headquartered in Bothell, Washington.

Today's Range

Now: $1.47

$1.46

$1.49

50 Day Range

MA: $1.49

$1.40

$1.60

2 Week Range

Now: $1.47

$1.33

$3.29

Volume

5,066 shs

Average Volume

13,756 shs

Market Capitalization

$14.95 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.34

Biden’s $374B Giveaway Into This Sector

From DTI | Ad

Biden’s Climate Bill Could Send Your Retirement Accounts Soaring – Or Diving See what this $374B giveaway could mean for your retirement right here

Click here for the full story